Intensity Therapeutics, Inc.
INTS
$3.96
-$0.04-1.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -18.74% | 38.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.55% | 14.89% | |||
| Operating Income | 19.55% | -14.89% | |||
| Income Before Tax | 20.22% | -14.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 20.22% | -14.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.22% | -14.23% | |||
| EBIT | 19.55% | -14.89% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 26.64% | 15.59% | |||
| Normalized Basic EPS | 26.65% | 15.58% | |||
| EPS Diluted | 63.35% | -68.94% | |||
| Normalized Diluted EPS | 26.65% | 15.58% | |||
| Average Basic Shares Outstanding | 8.76% | 35.32% | |||
| Average Diluted Shares Outstanding | 8.76% | 35.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||